Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice

Bibliography

• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol 2013. [Epub ahead of print]
   Google Scholar
• Moyer VA. Screening for and management of obesity in adults: U.S. preventive services task force recommendation. Ann Intern Med 2012;157:373-8
   PubMed Web of Science ®Google Scholar
• Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 1989;13:123-36
   PubMed Web of Science ®Google Scholar
• Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000;1:113-19
   PubMedGoogle Scholar
• Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes 2005;29:1153-67
   PubMed Web of Science ®Google Scholar
• Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behaviour therapy, and their combination: a five-year perspective. Int J Obes 1989;13(Suppl 2):39-46
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program (DPP) Research Group. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165-71
   PubMed Web of Science ®Google Scholar
• The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-83
   PubMed Web of Science ®Google Scholar
• Stafford RS, Radley DC. National Trends in antiobesity medication use. Arch Intern Med 2003;163:1046-50
   PubMedGoogle Scholar
• Ryan DH, Kushner R. The state of obesity and obesity research. JAMA 2010;304:1835-6
   PubMedGoogle Scholar
• Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in swedish obese subjects. N Engl J Med 2012;367:695-701
   PubMed Web of Science ®Google Scholar
• Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61
   PubMed Web of Science ®Google Scholar
• Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41
   PubMedGoogle Scholar
• Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-20
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother 2009;10:921-5
   PubMed Web of Science ®Google Scholar
• Guerciolini R. Mode of action of orlistat. Int J Obes 1997;21:S12-23
   PubMed Web of Science ®Google Scholar
• Berthoud HR. Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 2002;26:393-428
   PubMed Web of Science ®Google Scholar
• Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95
   PubMed Web of Science ®Google Scholar
• Gadde KM. Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:549-56
   PubMedGoogle Scholar
• Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes 2009;16:353-8
   PubMedGoogle Scholar
• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6
   PubMed Web of Science ®Google Scholar
• Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Healy D, et al. Efficacy of exogenous recombinant murine leptin in lean and obese 10- to 12-mo-old female CD1 mice. Am J Physiol 1998;275:R950-9
   Google Scholar
• Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736-43
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company Limited new release. Amylin and Takeda discontinue development of pramlintide/metreleptin combination treatment for obesity following commercial reassessment of the program. 2011. Available from: http://www.takeda.com/news/2011/20110805_3889.html [Accessed 27 November 2013]
   Google Scholar
• Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984;115:427-9
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-71
   PubMed Web of Science ®Google Scholar
• Parker EM, Balasubramaniam A, Guzzi M, et al. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 2000;21:393-9
   PubMedGoogle Scholar
• Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4:275-80
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41
   PubMed Web of Science ®Google Scholar
• James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-15
   PubMed Web of Science ®Google Scholar
• Prescribing information for Effexor XR (venlafaxine hydrochloride) extended release capsules. Wyeth Pharmaceuticals, Inc., Philadelphia, PA; 2013
   Google Scholar
• Ermer J, Haffey MB, Richards C, et al. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Investig 2013;33:243-54
   PubMedGoogle Scholar
• Diaper A, Rich AS, Wilson SJ, et al. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nature Neurosci 2005;8:585-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Press release. the european medicines agency recommends suspension of the marketing authorisation of acomplia. London, 23 October 2008. Doc. Ref. EMEA/CHMP537777/2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf [Accessed 27 November 2013]
   Google Scholar
• Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006;114:974-84
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes 2010;34:919-35
   Web of Science ®Google Scholar
• Proietto J, Rissanen A, Harp JB, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes 2010;34:1243-54
   Web of Science ®Google Scholar
• Aronne LJ, Finer N, Hollander PA, et al. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring) 2011;19:1404-14
   PubMed Web of Science ®Google Scholar
• European Agency for the Evaluation of Medicinal Products. Press Release, 9 September, 1999. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500017629.pdf [Accessed 27 November 2013]
   Google Scholar
• Bird & Bird, Cooley Godward. Legal and regulatory update: EU health ministers reach agreement on the commission's proposals for pharmaceutical reform. J Commercial Biotech 2003;10:177-85
   Google Scholar
• Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med 2003;163:1046-50
   PubMedGoogle Scholar
• Melnikova I, Wages D. Anti-obesity therapies. Nature Rev Drug Discov 2006;5:369-70
   PubMed Web of Science ®Google Scholar
• Wong D, Sullivan K, Heap G. The pharmaceutical market for obesity therapies. Nature Rev Drug Discov 2012;11:669-70
   PubMedGoogle Scholar
• Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the united states. Pharmacotherapy 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: quantitative analysis of four decades of published randomized controlled trials. Int J Obes 2002;26:262-73
   PubMed Web of Science ®Google Scholar
• Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Brit Med J 1968;1:352-4
   PubMed Web of Science ®Google Scholar
• Silverstone T. Appetite suppressants: a review. Drugs 1992;43:820-36
   PubMed Web of Science ®Google Scholar
• Prescribing information for Suprenza^™ (phentermine hydrochloride) orally disintegrating tablet. Akrimax Pharmaceuticals, Cranford, NJ, USA; 2012
   Google Scholar
• Food and Drug Administration. Guidance for industry developing products for weight management, draft guidance, revision 1. Center for drug evaluation and research (CDER), food and drug administration, Rockville, MD; 2007. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf [Accessed 27 November 2013]
   Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products used in weight control. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency, London, UK; 2007. Doc. Ref. CPMP/EWP/281/96 Rev.1. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003264.pdf [Accessed 27 November 2013]
   Google Scholar
• Bray GA. Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 2013;21:893-9
   PubMedGoogle Scholar
• Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight and obese adults: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Behavior modification and lorcaserin for overweight and obesity management (BLOOM) study group: multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-42
   PubMed Web of Science ®Google Scholar
• Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research: limitations of methods, measurements, and medications. JAMA 2006;295:826-8
   PubMed Web of Science ®Google Scholar
• Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 2003;4:175-84
   PubMedGoogle Scholar
• Elobeid MA, Padilla MA, McVie T, et al. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One 2009;4:e6624
   PubMed Web of Science ®Google Scholar
• Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012;172:1557-64
   PubMedGoogle Scholar
• Montedori A, Bonacini MI, Casazza G, et al. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials 2011;12:58
   PubMed Web of Science ®Google Scholar
• Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive services task force. Ann Intern Med 2011;155:434-47
   PubMed Web of Science ®Google Scholar
• Yanovski SN, Yanovski JA. Long-term drug treatment of obesity: a systematic and clinical review. JAMA 2013. [Epub ahead of print]
   Google Scholar
• Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes 2007;31:1567-70
   PubMed Web of Science ®Google Scholar
• Xu Y, Jones JE, Kohno D, et al. 5-HT-2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008;60:582-9
   PubMed Web of Science ®Google Scholar
• Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-87
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009;8:317-29
   PubMed Web of Science ®Google Scholar
• Abramowski D, Rigo M, Duc D, et al. Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995;34:1635-45
   PubMed Web of Science ®Google Scholar
• Sharma A, Punhani T, Fone KC. Distribution of the 5-hydroxytryptamine 2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine. Synapse 1997;27:45-56
   PubMed Web of Science ®Google Scholar
• Clemett DA, Punhani T, Duxon MS, et al. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 2000;39:123-32
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-77
   PubMed Web of Science ®Google Scholar
• O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-36
   PubMed Web of Science ®Google Scholar
• Prescribing information for Belviq® (lorcaserin HCl) for oral use, CIV. Arena Pharmaceuticals, Zofingen, Switzerland, and Eisai, Inc., Woodcliff Lake, NJ; 2012
   Google Scholar
• Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs fro chronic weight management. N Engl J Med 2012;367:1577-8
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-85
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20
   PubMed Web of Science ®Google Scholar
• Dunkley EJ, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-42
   PubMed Web of Science ®Google Scholar
• Isbister GK, Whyte IM. Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. Br J Anaesth 2002;88:603-4
   PubMedGoogle Scholar
• Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000;79:201-9
   PubMed Web of Science ®Google Scholar
• Ables AZ, Nagubilli R. Prevention, diagnosis, and management of serotonin syndrome. Am Fam Physician 2010;81:1139-42
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41
   PubMed Web of Science ®Google Scholar
• Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189-99
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitão CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 2011;12:e338-47
   PubMed Web of Science ®Google Scholar
• Rubino DM, Gadde KM. A review of topiramate and phentermine: a combined therapeutic approach to obesity. Clin Lipidol 2012;7:13-25
   Web of Science ®Google Scholar
• Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6:131-9
   PubMedGoogle Scholar
• Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007;30:1480-6
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Rössner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naïve type 2 diabetes. Diabetes Obes Metab 2007;9:360-8
   PubMed Web of Science ®Google Scholar
• Eliasson B, Gudbjörnsdottir S, Cederholm J, et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 2007;31:1140-7
   PubMed Web of Science ®Google Scholar
• Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 2007;31:138-46
   Web of Science ®Google Scholar
• Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother 2009;10:921-5
   PubMed Web of Science ®Google Scholar
• Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143-8
   PubMed Web of Science ®Google Scholar
• Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine an placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269-77
   PubMed Web of Science ®Google Scholar
• Gadde KM, Yonish GM, Foust MS, et al. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults [abstract 406-P]. Obes Res 2006;14:A17
   Google Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013. [Epub ahead of print]
   Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov Identifier NCT 00796367. A safety and efficacy study of VI-0521 to evaluate the long-term treatment of obesity in adults with obesity-related comorbid conditions. An extension of protocol OB-303 (NCT00553787). Available from: http://clinicaltrials.gov/ct2/show/NCT00796367?term=vivus&rank=20 [Accessed 27 November 2013]
   Google Scholar
• Food and Drug Administration. Advisory Committee Meeting for Phentermine/Topiramate (Qnexa). Division of Metabolism and Endocrinology Products (DMEP), Office of Drug Evaluation II, Center for Drug Evaluation and Research, Silver Spring, MD; 2010. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218819.htm [Accessed 27 November 2013]
   Google Scholar
• Hunt S, Russell WH, Smithson L, et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 2008;71:272-6
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9
   PubMed Web of Science ®Google Scholar
• Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405e1-7
   Google Scholar
• Vivus, Inc. NDA 22580. Qsymia (phentermine and topiramate extended-release) Capsules: risk evaluation and mitigation strategy (REMS). Initial REMS approval, 07/2012; most recent modification, 04/2013. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312598.pdf [Accessed 27 November 2013]
   Google Scholar
• Vivus, Inc. Press Release. Vivus updates European filing strategy for Qsiva. Vivus, Inc., Mountain View, CA; 2013. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=791927 [Accessed 27 November 2013]
   Google Scholar
• Prescribing information for Qsymia® (phentermine and topiramate extended-release capsules, for oral use, CIV. Vivus, Inc., Mountain View, CA; 2013
   Google Scholar
• European Medicines Agency. Refusal of the marketing authorisation for Qsiva (phentermine/topiramate): outcome of re-examination. European Medicines Agency, London, UK; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf [Accessed 27 November 2013]
   Google Scholar
• European Medicines Agency. Withdrawal of the marketing authorisation application for Belviq (lorcaserin). European Medicines Agency, London, UK; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143811.pdf [Accessed 27 November 2013]
   Google Scholar
• Gadde KM, Xiong GL. Bupropion for weight reduction. Exp Rev Neurother 2007;7:17-24
   PubMedGoogle Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009;17:30-9
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA briefing document: NDA 200063. Contrave (Naltrexone 4mg, 8mg/Bupropion HCL 90mg extended release tablet). Advisory Committee Meeting for naltrexone/bupropion (Contrave). Division of Metabolism and Endocrinology Products (DMEP), Office of Drug Evaluation II, Center for Drug Evaluation and Research, Silver Spring, MD; 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235671.pdf [Accessed 27 November 2013]
   Google Scholar
• Orexigen Therapeutics. Press Release. Orexigen announces successful interim analysis of Contrave Light study. Orexigen Therapeutics, La Jolla, CA; 2013. Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1879629&highlight [Accessed 27 November 2013]
   Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013;37:1443-51
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012;36:843-54
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE - obesity and pre-diabetes. Available from: http://clinicaltrials.gov/ct2/show/NCT01272219?term=liraglutide+obesity+phase+III&rank=2 [Accessed 27 November 2013]
   Google Scholar
• Novo Nordisk. Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE – diabetes. Available from: http://clinicaltrials.gov/ct2/show/NCT01272232?term=liraglutide+obesity+phase+III&rank=3 [Accessed 27 November 2013]
   Google Scholar
• Rissanen A, Lean M, Rössneer S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003;27:103-9
   PubMedGoogle Scholar
• Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006;8:206-13
   PubMedGoogle Scholar
• Rössner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European orlistat obesity study group. Obes Res 2000;8:49-61
   PubMedGoogle Scholar
• Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008;29:1761-71
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42
   PubMed Web of Science ®Google Scholar
• Holzapfel C, Cresswell L, Ahern AL, et al. The challenge of a 2-year follow-up after intervention for weight loss in primary care. Int J Obes 2013. [Epub ahead of print]
   Google Scholar
• Mustajoki P, Pekkarinen T. Maintenance programmes after weight reduction – how useful are they? Int J Obes Relat Metab Disord 1999;23(6):553-5
   PubMedGoogle Scholar
• Jeffery RW, Drewnowski A, Epstein LH, et al. Long-term maintenance of weight loss: current status. Health Psychol 2000;19(Suppl 1):5-16
   PubMed Web of Science ®Google Scholar
• Perri MG, Foreyt JP. Preventing weight gain after weight loss. In: Bray GA, Bouchard, editors, Handbook of obesity: clinical applications. 2nd edition. Marcel Dekker, Inc., New York NY; 2004. p. 185-99
   Google Scholar